Caraway Therapeutics, an emerging biopharma based in Cambridge, MA, has expanded its leadership team with the addition of industry veteran Martin D Williams as CEO.
Mr Williams brings more than three decades of global biopharma experience to Caraway, including public and venture-backed biotechnology firms and multinational pharmaceutical companies.
He was most recently Executive Chairman of Yuma Therapeutics, a company focused on neurodegenerative conditions which he co-founded. He will remain on Yuma’s board of directors.
Previously, he held a series of leadership roles at pharmaceutical companies, including President and CEO of Tokai Pharmaceuticals, and Chief Business Officer of Dicerna Pharmaceuticals and Synta Pharmaceuticals.
Caraway Therapeutics is pursuing novel approaches for the treatment of debilitating neurodegenerative diseases by preserving neurons.
“Neurodegenerative diseases are among the greatest unmet medical and public health needs. Caraway’s rigorous scientific approach supported by human genetic data, renowned co-founders and dedication to developing treatments for patients compelled me to join the company,” said Mr. Williams.
“I look forward to working with the team to continue advancing our science toward the clinic for the benefit of patients suffering from these devastating diseases.”